Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities
International Journal of Molecular Sciences · 27.06.2024 · 25 (13) · 7056
DOI: 10.3390/ijms25137056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.06.2024. Verfasst von Stefano Sol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. Hauptthemen laut MEDLINE: Skin Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Skin cancer encompasses a range of cutaneous malignancies, with non-melanoma skin cancers (NMSCs) being the most common neoplasm worldwide. Skin exposure is the leading risk factor for initiating NMSC. Ultraviolet (UV) light induces various genomic aberrations in both tumor-promoting and tumor-suppressing genes in epidermal cells. In conjunction with interactions with a changed stromal microenvironment and local immune suppression, these aberrations contribute to the occurrence and expansion of cancerous lesions. Surgical excision is still the most common treatment for these lesions; however, locally advanced or metastatic disease significantly increases the chances of morbidity or death. In recent years, numerous pharmacological targets were found through extensive research on the pathogenic mechanisms of NMSCs, leading to the development of novel treatments including Hedgehog pathway inhibitors for advanced and metastatic basal cell carcinoma (BCC) and PD-1/PD-L1 inhibitors for locally advanced cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC). Despite the efficacy of these new drugs, drug resistance and tolerability issues often arise with long-term treatment. Ongoing studies aim to identify alternative strategies with reduced adverse effects and increased tolerability. This review summarizes the current and emerging therapies used to treat NMSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
- Drexel University College of Medicine, 60 N 36th Street, Philadelphia, PA 19104, USA.
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA.
- Harvard Stem Cell Institute, 7 Divinity Avenue, Cambridge, MA 02138, USA.
ORCID-Profile: Stefano Sol, Fabiana Boncimino, Anna Mandinova
Zitieren
APA
Sol, S., Boncimino, F., Todorova, K., Waszyn, S. E., & Mandinova, A. (2024). Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities. International Journal of Molecular Sciences, 25(13), 7056. https://doi.org/10.3390/ijms25137056
Vancouver
Sol S, Boncimino F, Todorova K, Waszyn SE, Mandinova A. Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities. International Journal of Molecular Sciences. 2024;25(13):7056. doi:10.3390/ijms25137056
BibTeX
@article{Sol2024,
author = {Sol, Stefano and Boncimino, Fabiana and Todorova, Kristina and Waszyn, Sarah Elizabeth and Mandinova, Anna},
title = {Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {7056},
doi = {10.3390/ijms25137056}
}
EUVIMED